Sökning: WFRF:(Fristrup Niels) >
Multicenter randomi...
Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors : the NORDIC-SUN-Trial
-
- Iisager, Laura (författare)
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
-
- Ahrenfeldt, Johanne (författare)
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
-
- Donskov, Frede (författare)
- Department of Oncology, Southern Denmark University Hospital, Esbjerg, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark
-
visa fler...
-
- Ljungberg, Börje, Professor, 1949- (författare)
- Umeå universitet,Institutionen för kirurgisk och perioperativ vetenskap
-
- Bex, Axel (författare)
- Specialist Centre for Kidney Cancer, Royal Free Hospital London, London, United Kingdom
-
- Lund, Lars (författare)
- Department of Urology, Odense University Hospital, Odense, Denmark
-
- Lyskjær, Iben (författare)
- Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
-
- Fristrup, Niels (författare)
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
-
visa färre...
-
(creator_code:org_t)
- BioMed Central (BMC), 2024
- 2024
- Engelska.
-
Ingår i: BMC Cancer. - : BioMed Central (BMC). - 1471-2407. ; 24:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Primary tumor removal by cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma patients has been investigated in the context of various treatment regimens. Two randomized controlled trials investigated the role and timing of cytoreductive nephrectomy in the era of targeted therapy and demonstrated that upfront nephrectomy should no longer be performed when patients require systemic therapy. Superiority of checkpoint immunotherapy agents has led to a paradigm change from targeted therapies to immunotherapy-based first-line treatment in patients with primary metastatic disease; thus, deferred cytoreductive nephrectomy needs to be verified in the immunotherapy setting. Furthermore, a need exists for personalizing treatment choices for the individual patient to avoid unnecessary overtreatment.Methods/design: To explore the impact of cytoreductive nephrectomy in this patient group receiving checkpoint immunotherapy, we initiated a randomized, controlled trial comparing deferred cytoreductive nephrectomy with no surgery. The trial integrates a comprehensive translational research program with specimen sampling for biomarker analysis.Discussion: The trial aims to show that deferred cytoreductive nephrectomy improves overall survival in patients with synchronous metastatic renal cell carcinoma, and furthermore, to identify relevant biomarkers for personalized renal cancer management.Trial registration: ClinicalTrials.gov NCT03977571 June 6, 2019.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Biomarkers
- Deferred cytoreductive nephrectomy
- Immunotherapy
- Synchronous metastatic renal cell carcinoma
- Translational research
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas